Portal de investigación
ENSAYO CLÍNICO FASE 1/2 DE UN BRAZO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DEL MESILATO DE ERIBULINA EN COMBINACIÓN CON IRINOTECÁN EN NIÑOS CON TUMORES SÓLIDOS REFRACTARIOS O RECURRENTES.
Datos básicos
- Código:
- E7389-G000-213
- Protocolo:
- E7389-G000-213
- EUDRACT:
- 2016-003352-67
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2018
- Año de finalización:
- 2021
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11611. 2021
A Confidence Habitats Methodology in MR Quantitative Diffusion for the Classification of Neuroblastic Tumors.
Cerda Alberich, Leonor; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers12123858. 2020
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain
Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro
Article. 10.33393/grhta.2022.2333. 2022
A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.
Zozaya, Neboa; (...); Verde, Luis
Article. 10.1017/S0266462322000459. 2022
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F; (...); Martínez-Olmos J
Article. 10.1007/s41669-020-00201-2. 2020
A NATIONAL PEDIATRIC NEURO-ONCOLOGY TUMOR BOARD INITIATIVE IN SPAIN: RESULTS OF A WEB-BASED SURVEY TO EVALUATE PARTICIPANT EXPERIENCE UTILIZING THIS RESOURCE
Illade, Laura; (...); Lassaletta, Alvaro
Article. 2022
A new definition and refocus of pharmaceutical care: the Barbate Document
Morillo-Verdugo R; (...); Poveda-Andrés JL
Article. 10.7399/fh.11389. 2020
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma
Van Hal, Gertjan; (...); Lewin, Jeremy Howard
Meeting Abstract. 2023
A rare case of diffuse and bilateral pulmonary uptake in 18 F-FDG PET/CT scan.
Olivan-Sasot, P; (...); Bello-Arques, P
Editorial Material. 10.1016/j.remn.2020.11.007. 2021
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
Adolescent cancer care: What has changed in Spain in the past decade?
Garrido Colino, Carmen; (...); Vagace Valero, Jose Manuel
Article. 10.1016/j.anpede.2023.01.003. 2023
Adolescent cancer care: What has changed in Spain in the past decade?
Garrido Colino, Carmen; (...); SEHOP
Article. 10.1016/j.anpedi.2022.09.012. 2023
Alectinib in pediatric patients with solid or CNS tumors harboring ALK-fusions: Emerging pharmacokinetic data from the iMATRIX alectinib phase I/II open-label, multi-center study
Doz, Francois; (...); Gajjar, Amar J.
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.3098. 2024
Analysing criteria for price and reimbursement of orphan drugs in Spain.
Badia, X; (...); Tort, M
Article. 10.7399/fh.11147. 2019
Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital
Valero García S; (...); Poveda Andrés JL
Article. 10.1177/10781552211038518. 2021
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
ASSESSMENT OF A NOVEL READY-TO-USE TEMOZOLOMIDE ORAL SUSPENSION IN CHILDREN WITH SOLID TUMORS: RESULTS OF TEMOKIDS, A POPULATION PHARMACOKINETIC, ACCEPTABILITY AND SAFETY PHASE-1 STUDY
Abbou, Samuel; (...); Metayer, Lucy
Meeting Abstract. 2023
Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma I-131-mIBG treatment
Chimeno, JM; (...); Montoro, A
Article. 10.1080/09553002.2019.1549755. 2018
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
Iglesias Gómez R; (...); Poveda Andrés JL
Article. 10.1136/ejhpharm-2021-002741. 2021
Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study.
de Beijer IAE; (...); Pluijm SMF
Article. 10.1007/s11764-023-01498-8. 2023
Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2018.12.027. 2019
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; (...); Hernandez D
Article. 10.1111/ctr.14550. 2022
Cadmium (Cd) and Lead (Pb) topsoil levels and incidence of childhood leukemias
Asenjo S; (...); Ramis R
Article. 10.1007/s10653-021-01030-w. 2021
Cáncer en los primeros 18 meses de vida.
Urtasun Erburu A, Herrero Cervera MJ, Cañete Nieto A
Article. 10.1016/j.anpedi.2020.02.015. 2020
Cancer is not a risk factor for severe COVID-19 in children, except in patients with recent allogeneic hematopoietic stem cell transplantation or comorbidities.
Velasco Puyó P; (...); Astigarraga I
Article. 10.1002/pbc.31120. 2024
Casuística de tumor miofibroblástico inflamatorio en centro terciario.
Martínez Navarro G; (...); Fernández Navarro JM
Case Reports. 10.1016/j.anpedi.2020.12.007. 2021
Casuistics of inflammatory myofibroblastic tumor in a tertiary center.
Martínez Navarro G; (...); Fernández Navarro JM
Case Reports. 10.1016/j.anpede.2020.12.016. 2021
Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience
Berlanga, P; (...); Ladenstein, R
Article. 10.1016/j.ejca.2020.10.020. 2021
Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients
Megias-Vericat, JE; (...); Poveda, JL
Article. 10.1016/j.thromres.2021.07.009. 2021
Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.
J Ribelles A; (...); Castel V
Article. 10.1038/s41598-019-50327-5. 2019
Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model
Nogueras, A; (...); Calleja, MA
Letter. 10.1136/ejhpharm-2019-001905. 2019
Cmo tratamos el hemangioendotelioma kaposiforme?
Huerta-Calpe S; (...); Pérez-Tarazona S
Article. 10.1016/j.anpedi.2018.09.002. 2019
Comparative Multicentric Evaluation of Inter-Observer Variability in Manual and Automatic Segmentation of Neuroblastic Tumors in Magnetic Resonance Images
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers14153648. 2022
Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo
Megias-Vericat, JE; (...); Poveda, JL
Meeting Abstract. 2020
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
Campbell, K; (...); DuBois, SG
Article. 10.1002/pbc.27819. 2019
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA
Gironella, M.; (...); Oyaguez, I
Meeting Abstract. 2019
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Poveda JL; (...); Torres C
Article. 10.1080/14737167.2019.1635014. 2020
COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN
Bonanad, S; (...); Gonzalez-Dominguez, A
Meeting Abstract. 2020
Costs of the management of hemophilia A with inhibitors in Spain
Bonanad, S; (...); Gonzalez-Dominguez, A
Article. 10.33393/grhta.2021.2234. 2021
Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis
Megias-Vericat, JE; (...); Poveda, JL
Letter. 10.1111/hae.13733. 2019
Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products
Eduardo Megias, Juan; (...); Iorio, Alfonso
Meeting Abstract. 10.1182/blood-2019-127946. 2019
Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP).
Gargallo, P.; (...); Moreno, L.
Article. 10.1007/s12094-021-02759-7. 2022
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP).
Rubio-San-Simon, A.; (...); Bautista, F.
Article. 10.1007/s12094-020-02399-3. 2021
Childhood and Adolescent Central Nervous System Tumours in Spain: Incidence and Survival over 20 Years: A Historical Baseline for Current Assessment.
Chirlaque MD; (...); The Spanish Childhood Cancer Epidemiology Working Group
Article. 10.3390/cancers15245889. 2023
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review
Megias-Vericat, JE; (...); Montesinos, P
Review. 10.1080/17512433.2019.1573668. 2019
Delving into the clinical impact of NETs in pediatric cancer.
Benavent N; (...); Medina P
Article. 10.1038/s41390-024-03437-4. 2024
Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.
Salinas P; (...); Escaned J
Article. 10.1016/j.carrev.2021.11.015. 2021
Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis
Alvarez-Roman, MT; (...); Badia, X
Article. 10.1177/2284240319880534. 2019
DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
Alvarez, E.; (...); Badia, F. J.
Meeting Abstract. 2019
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
Poveda, J. L.; (...); Vitoria, I
Meeting Abstract. 2019
Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain
Badia, X; (...); Poved, JL
Article. 10.1080/21678707.2019.1652163. 2019
Development of the ECLIM-SEHOP Clinical Trial Platform: Implementing International Academic Clinical Trials for Childhood Cancer and Blood Disorders in Spain
Fernandez-Teijeiro, A; (...); Moreno, L
Meeting Abstract. 2020
Distribution of segmental chromosomal alterations in neuroblastoma.
Juan Ribelles A; (...); Castel V
Article. 10.1007/s12094-020-02497-2. 2020
ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain.
Bautista, F; (...); Sociedad Española de Hematología y Oncología Pediátrica (SEHOP)
Article. 10.1007/s12094-019-02221-9. 2019
ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer.
Juan-Ribelles A; (...); Fernández-Teijeiro A
Article. 10.1007/s12094-024-03445-0. 2024
Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.
Torres Martínez E; (...); Vento M
Article. 10.1016/j.anpedi.2020.03.009. 2020
Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment
Palanques-Pastor T; (...); Poveda Andrés JL
Article. 10.1159/000517813. 2021
Eighteen years of experience with pediatric nutcracker syndrome: the importance of the conservative approach.
Miró I; (...); Domínguez C
Article. 10.1016/j.jpurol.2019.12.003. 2020
Endocrinological late effects of oncologic treatment on survivors of medulloblastoma
Santos, ADH; (...); Nieto, AC
Article. 10.32641/rchped.v90i6.994. 2019
Enteric duplication cysts in children: varied presentations, varied imaging findings
Nebot, CS; (...); Pradas, VI
Review. 10.1007/s13244-018-0660-z. 2018
EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
Badia, F. J.; (...); Shepherd, J.
Meeting Abstract. 2019
Evaluation of circulating tumor DNA by electropherogram analysis and methylome profiling in high-risk neuroblastomas
Trinidad, Eva Maria; (...); de Mora, Jaime Font
Article. 10.3389/fonc.2023.1037342. 2023
Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study.
Morini M; (...); Varesio L
Article. 10.3390/cancers11101476. 2019
EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
F, de Andres-Nogales; (...); Martinez, M.
Meeting Abstract. 2019
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report
Fernandez-Sanchez, M; (...); Poveda-Andres, JL
Article. 10.1002/bdr2.1942. 2021
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Bellini, Angela; (...); Schleiermacher, Gudrun
Article. 10.1200/JCO.21.00086. 2021
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care.
Gargallo P; (...); Cañete A
Article. 10.3390/cancers13215339. 2021
Germline variant in Ctcf links mental retardation to Wilms tumor predisposition
Gargallo, Pablo; (...); Font de Mora, Jaime
Article. 10.1038/s41431-022-01105-x. 2022
Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis
Editorial Material. 2022
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.
El-Qutob D; (...); Carrera-Hueso FJ
Article. 10.1016/j.hrtlng.2022.02.003. 2022
High Oct4 expression: implications in the pathogenesis of neuroblastic tumours
Monferrer, E; (...); Noguera, R
Article. 10.1186/s12885-018-5219-3. 2019
HIGH RISK NEUROBLASTOMA (HR-NB) WITH MNA AND AGE
Ladenstein, Ruth; (...); Canete, Adela
Meeting Abstract. 2023
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial
Ladenstein, Ruth Lydia; (...); Canete, Adela
Meeting Abstract. 2023
High-risk neuroblastoma: where do we go?
Editorial Material. 10.1016/j.annonc.2019.12.003. 2020
Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies
Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo
Article. 10.7399/fh.11729. 2022
Hospitalization budget impact during the COVID-19 pandemic in Spain.
Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.
Article. 10.1186/s13561-021-00340-0. 2021
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Imaging biomarkers and radiomics in pediatric oncology: a view from the PRIMAGE (PRedictive In silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers) project.
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.1007/s00247-023-05770-y. 2023
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium.
Rubio-San-Simón A; (...); Bautista F
Article. 10.1016/j.ejca.2020.09.024. 2020
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
Badia X; (...); Hernández C
Article. 10.1186/s13023-020-01507-4. 2020
Impact of voriconazole plasma concentrations on treatment response in critically ill patients
Ruiz, J; (...); Ramirez, P
Article. 10.1111/jcpt.12817. 2019
Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases
Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL
Article. 10.7399/fh.11262. 2020
Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR Images
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.3390/cancers15051622. 2023
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic
Faura, A; (...); Dapena, JL
Letter. 10.1002/pbc.28557. 2020
International benchmarking of childhood cancer survival by tumour stage: First results of the BENCHISTA project
Pritchard-Jones, K.; (...); Gatta, G.
Meeting Abstract. 2024
International benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study.
Botta, Laura; (...); Pritchard-Jones, Kathy
Article. 10.1016/S2352-4642(24)00302-X. 2025
Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report
Company-Albir, MJ; (...); Poveda, JL
Article. 10.1111/jcpt.12842. 2019
Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.
Coronado, Esther; (...); Font de Mora, Jaime
Article. 10.1002/1878-0261.12868. 2021
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.
Solana-Altabella A; (...); Poveda JL
Article. 10.1177/1078155220904410. 2020
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19
Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP
Article. 10.1136/ejhpharm-2020-002322. 2020
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
IT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey.
de Beijer, Ismay A E; (...); Chronaki, Catherine
Article. 10.2196/49910. 2024
Lateral-type posterior fossa ependymomas in pediatric population
Miranda-Lloret, Pablo; (...); Llavador, Gemma
Article. 10.1016/j.neucir.2023.10.002. 2024
Lateral-type posterior fossa ependymomas in pediatric population.
Miranda-Lloret, Pablo; (...); Llavador, Gemma
Article. 10.1016/j.neucie.2023.10.001. 2024
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050) : a multicentre, open-label, multicohort, phase 1/2 study
Gaspar, N; (...); Campbell-Hewson, Q
Article. 10.1016/S1470-2045(21)00387-9. 2021
Li-Fraumeni syndrome heterogeneity.
Gargallo P; (...); Cañete A
Review. 10.1007/s12094-019-02236-2. 2020
Li-Fraumeni: Will the detection in families increase the survival of its members?
Gargallo, P; (...); Canete, A
Letter. 10.1016/j.anpedi.2018.03.009. 2019
Liquid Biopsies Provide Exosomal MicroRNAs as Biomarkers of the Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients
Morini, M; (...); Varesio, L
Meeting Abstract. 2018
Liquid Biopsy Micro-RNA Profiling in Meduloblastoma
Yanez, Y; (...); Canete, A
Meeting Abstract. 2018
Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA.
Trinidad EM; (...); Font de Mora J
Article. 10.1093/bib/bbac575. 2023
Long-Term Results for Infants with Neuroblastoma Treated Between 2000 and 2D004 According to INES Protocols -INESFU- A SIOPEN Study
Munzer, C; (...); Gambart, M
Meeting Abstract. 2019
Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.
Megías-Vericat JE; (...); Poveda-Andrés JL
Article. 2021
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
Bonanad, S; (...); Santos, S
Article. 10.1007/s12325-021-01853-0. 2021
Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Article. 10.3390/cancers14030596. 2022
Methodological advances in the discovery of novel neuroblastoma therapeutics.
Segura MF; (...); Moreno L
Article. 10.1080/17460441.2022.2002297. 2022
Metyrapone as treatment in the neonatal McCune-Albright syndrome
de Mingo, Carmen; (...); Garcia-Robles, Ana
Article. 10.1515/jpem-2020-0036. 2020
Modeling Cardiotoxicity in Pediatric Oncology Patients Using Patient-Specific iPSC-Derived Cardiomyocytes Reveals Downregulation of Cardioprotective microRNAs.
Reinal, Ignacio; (...); Sepulveda, Pilar
Article. 10.3390/antiox12071378. 2023
Monitoring coagulation factors during surgery. A systematic review
Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11766. 2021
Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
Valero-García S; (...); Delgado-Sánchez O
Article. 10.7399/fh.11655. 2021
Mortality and survival rates in children and adolescents enrolled in early phase trials with a dose-finding/dose-confirmation component: An innovative therapies for children with cancer (ITCC) study.
Carceller, F; (...); Moreno, L
Meeting Abstract. 2019
MR Denoising Increases Radiomic Biomarker Precision and Reproducibility in Oncologic Imaging
Fernández Patón M; (...); Martí-Bonmatí L
Article. 10.1007/s10278-021-00512-8. 2021
MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
Rodriguez D; (...); Jaspan T
Article. 10.1148/radiol.211464. 2022
MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients
Olivera, GG; (...); Herrero, MJ
Article. 10.3390/ijms21082714. 2020
Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments
Gomez-Cebrian, N; (...); Pineda-Lucena, A
Review. 10.3390/cancers13184544. 2021
National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)
Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel
Correction. 10.7399/fh.11740. 2021
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
Neonatal Suprarenal Masses: An Observational Approach
Papadakis, V; (...); Canete, A
Meeting Abstract. 2018
Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries - A study by the Joint Action on Rare Cancers.
Cañete A; (...); Spanish Neuroblastoma Linkage Working Group (SpNbLinkWG)
Article. 10.1016/j.canep.2022.102145. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas
Ribelles, AJ; (...); Canete, A
Article. 10.3390/jpm11040268. 2021
Non-traumatic spleen disorders in children. Assessment by imaging
Nebot, CS; (...); Pico Aliaga, S.
Article. 10.1016/j.rx.2018.07.007. 2019
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
Optimising Urinary Catecholamine Diagnostics for Neuroblastoma Patients
Matser, Y; (...); Tytgat, G
Meeting Abstract. 2020
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
Nobre, L; (...); Tabori, U
Meeting Abstract. 2020
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.
Nobre L; (...); Tabori U
Article. 10.1200/PO.19.00298. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
Garcia-Robles, Ana; (...); Carrascosa, MA
Article. 10.3389/fped.2020.00372. 2020
Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Correction. 10.3389/fped.2021.834454. 2022
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project
Morillo-Verdugo, R; (...); Diaz-Olmo, J
Article. 10.7399/fh.11719. 2021
Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.
Morillo-Verdugo R; (...); Díaz-Olmo J
Article. 2021
Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy.
Urtasun, Andrea; (...); Herrero, Maria Jose
Article. 10.3390/cancers15051424. 2023
Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy
Margusino-Framiñán L; (...); Morillo-Verdugo R
Article. 10.7399/fh.11498. 2020
Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
Olivera, Gladys; (...); Alino, Salvador F.
Review. 10.20517/cdr.2018.25. 2019
Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?
Olivera, GG; (...); Herrero, MJ
Review. 10.3390/ijms22189815. 2021
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacometabolomics by NMR in Oncology: A Systematic Review.
Gómez-Cebrián N; (...); Pineda-Lucena A
Article. 10.3390/ph14101015. 2021
Pharmacotherapeutic management of advanced therapy medicinal products
Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia
Article. 10.7399/fh.13036. 2022
Phase 1 Combination Dose-Finding/Phase 2 Expansion Cohorts of Lenvatinib plus Etoposide plus Ifosfamide in Patients Aged 2 to <= 25 Years with Relapsed/Refractory Osteosarcoma
Gaspar, N; (...); Campbell-Hewson, Q
Meeting Abstract. 2019
Phase 1 Study of Regorafenib in Combination With Vincristine and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Casanova, M; (...); Geoerger, B
Meeting Abstract. 2020
Phase I combination dose-finding/phase II expansion cohorts of lenvatinib plus etoposide plus ifosfamide in patients (pts) aged 2 to <= 25 years with relapsed/refractory (r/r) osteosarcoma
Gaspar, N; (...); Campbell-Hewson, Q
Meeting Abstract. 2019
Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.
Casanova, Michela; (...); Geoerger, Birgit
Meeting Abstract. 2020
Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050) ? .
Gaspar N; (...); Casanova M
Article. 10.1016/j.esmoop.2021.100250. 2021
PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS
Vericat, JEM; (...); Iorio, A
Meeting Abstract. 2020
Plasma Metabolomic Profiling Differentiates High- and Low-Risk Neuroblastoma Patients
Quintas, G; (...); Segura, V
Meeting Abstract. 2018
Precision medicine in Ewing sarcoma: a translational point of view.
Gargallo P; (...); Cañete A
Review. 10.1007/s12094-020-02298-7. 2020
PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS
Garcia, EG; (...); Ivorra, JAR
Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019
Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.
García-Robles A; (...); Aguar-Carrascosa M
Letter. 10.1016/j.anpedi.2020.06.008. 2021
Preparation and administration of insulin infusions in neonatology: A national survey.
Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta
Article. 10.1016/j.anpede.2020.06.015. 2021
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers.
Martí-Bonmatí L; (...); Neri E
Article. 10.1186/s41747-020-00150-9. 2020
Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose
Review. 10.7399/fh.11780. 2021
Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study
Carceller, Fernando; (...); Moreno, Lucas
Meeting Abstract. 2023
Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.
Juan Ribelles A; (...); Castel V
Correction. 10.1038/s41598-020-58428-2. 2020
Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial.
Rodriguez Gutierrez D; (...); Jaspan T
Article. 10.1158/1078-0432.CCR-19-3154. 2020
Radiotherapy quality assurance in paediatric clinical trials: first report from six QUARTET-affiliated trials.
Kelly, Sarah M.; (...); Mandeville, Henry
Article. 10.1016/j.radonc.2023.109549. 2023
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A)
Lassaletta, Alvaro; (...); Juan-Ribelles, Antonio
Meeting Abstract. 2023
Regorafenib Plus Vincristine and Irinotecan in Pediatric Patients With Recurrent/Refractory Solid Tumors: An Innovative Therapies for Children With Cancer Study.
Casanova M; (...); Geoerger B
Article. 10.1158/1078-0432.CCR-23-0257. 2023
Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.
Veiga-Canuto, Diana; (...); Marti-Bonmati, Luis
Article. 10.1148/ryai.230208. 2024
Results of a survey on the treatment of adolescents and young adult (AYA) sarcoma patients in Spain at present time.
Mata Fernandez, Cristina; (...); Morales CV
Article. 10.1007/s12094-022-02912-w. 2022
Retinoblastoma and mosaic 13q deletion: a case report
Gargallo P; (...); Canete, A
Article. 10.1186/s40942-021-00321-9. 2021
Review: Ewing Sarcoma Predisposition.
Gargallo P; (...); Cañete A
Article. 10.1007/s12253-019-00765-3. 2019
Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study
Morgenstern, DA; (...); Ladenstein, R
Article. 10.1002/pbc.27363. 2018
Safety and PK (pharmacokinetic) profile of niraparib (nir) plus dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study
Doz, Francois; (...); Rubio-San-Simon, Alba
Meeting Abstract. 2023
SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.
Pérez-Encinas M; (...); Calleja-Hernández MÁ
Article. 10.7399/fh.11565. 2020
Single-Agent Expansion Cohort of Lenvatinib and Combination Dose-Finding Cohort of Lenvatinib plus Etoposide plus Ifosfamide in Patients Aged 2 to <= 25 Years with Relapsed/Refractory Osteosarcoma
Gaspar, N; (...); Campbell-Hewson, Q
Meeting Abstract. 2018
SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization
Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis
Article. 10.1111/jcpt.13703. 2022
Spontaneous spermatic vein thrombosis in pediatric patients: A condition to be considered.
Pérez-Ardavín J; (...); Domínguez Hinarejos C
Review. 2020
Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot study.
Gatta G; (...); JARC Pilot Study Toronto Guidelines Working Group
Article. 10.1002/pbc.29020. 2021
Suprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results
Papadakis, Vassilios; (...); Canete, Adela
Article. 10.3390/cancers14164007. 2022
Survival and Health Care Burden of Children With Retinoblastoma in Europe.
Virgili G; (...); Gatta G
Article. 10.1001/jamaophthalmol.2024.4140. 2024
Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
Megías-Vericat JE; (...); Montesinos P
Review. 10.3390/pharmaceutics14040878. 2022
Testicular tumours in children: an approach to diagnosis and management with pathologic correlation
Sanguesa, C; (...); Serrano, A
Review. 10.1186/s13244-020-00867-6. 2020
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
THE BENCHISTA PROJECT: INTERNATIONAL BENCHMARKING OF CHILDHOOD CANCER SURVIVAL BY TUMOUR STAGE
Cortes, Angela Lopez; (...); Pritchard-Jones, Kathy
Article. 2022
The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; (...); Gil A
Article. 10.1016/j.yebeh.2022.108711. 2022
The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Rubio-San-Simon, A.; (...); Moreno, L.
Article. 10.1007/s12094-021-02649-y. 2021
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.
Marques MR; (...); Mangas-Sanjuan V
Article. 10.1111/apa.14944. 2020
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy
Del Rio-Bermudez, C; (...); Poveda, JL
Editorial Material. 10.1186/s40545-020-00276-6. 2020
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma
Burgos-Panadero, R; (...); Noguera, R
Article. 10.1016/j.ijpharm.2021.121058. 2021
Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy
Garcia, SV; (...); Andres, JLP
Article. 10.1016/j.yrtph.2018.10.002. 2018
Use of [(18)F]fluorocholine PET/CT in the detection of primary hyperparathyroidism in paediatrics: a case report.
Martínez Sánchez H; (...); Sánchez Vañó R
Case Reports. 10.1515/jpem-2023-0556. 2024
USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Dominguez Hernandez, L.; (...); Gomez Segui, I
Meeting Abstract. 2019
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023
Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma
Burgos-Panadero, R; (...); Noguera, R
Article. 10.1186/s12885-019-5693-2. 2019
Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?
Lopez-Carrasco, Amparo; (...); Noguera, Rosa
Article. 10.3390/ijms25168733. 2024